Print

Print


Tuberculosis drug may cure Parkinson's-like illness
Jun. 7, 2006



  Researchers have discovered that a drug used to treat tuberculosis
apparently cures patients of a Parkinson's-like illness suffered by thousands
of mineworkers, welders and others exposed to high levels of the metal
manganese. Manganese is used to produce steel alloys and as a coating on
welding rods, among other industrial applications. It replaced lead decades
ago as a component in unleaded gasoline, increasing the risks of manganese
intoxication for the general public, said one of the researchers, Wei Zheng,
a professor and University Faculty Scholar in Purdue's School of Health
Sciences. When manganese builds up in toxic levels in the body, people suffer
from "occupational manganese parkinsonism," which causes symptoms similar to
Parkinson's disease. Victims experience hand tremors, poor coordination,
unsteady gait and a masklike inability to show facial expressions, Zheng
said. Manganese contained in the coating of welding rods is released in
fumes. Welders involved in manufacturing vehicles, tanks and ships are
especially prone to manganese intoxication because they work in close
quarters, increasing their exposure to the metal, Zheng said. "There are
about 430,000 welders in the United States alone, and even more in China, so
manganese intoxication likely affects many people, including workers involved
in manganese mining and steel production," he said. "In Beijing, we found a
high percentage of welders have these symptoms." While the condition's
symptoms are similar to those of Parkinson's disease, the standard treatments
for Parkinson's disease, including the drug levodopa, are not effective for
manganese intoxication. A chemical compound called EDTA has been used to help
patients eliminate manganese in the urine. The drug's effectiveness, however,
is limited because it is water-soluble, preventing it from readily passing
through membranes in the "blood-brain barrier," layers of cells surrounding
blood vessels that block substances from traveling from the blood into brain
tissue. Ten researchers from institutions around the world - including Purdue
- conducted a 17-year medical follow-up study on a manganese-poisoned worker
and about 80 other patients. The researchers learned that an aspirinlike drug
called sodium para-aminosalicylic acid, or PAS, dramatically reduces symptoms
on a long-term basis. "The amazing thing is that this drug reverses
Parkinson-type symptoms of manganese intoxication," Zheng said. "We see
remarkable improvement after treatment with this drug even 17 years later."
PAS has been used for decades to treat tuberculosis and apparently can cross
the blood-brain barrier because it is fat-soluble, or lipophilic. That's
because the drug contains a structure known as a benzene ring, which enables
it to penetrate the membranes. Findings will appear in the June issue of the
Journal of Occupational Environmental Medicine. The paper was written by
Yue-Ming Jiang, Xue-An Mo, Feng-Qi Du, Xue Fu and Xia-Yan Zhu, from Guangxi
Medical University in China; Hong-Yu Gao and Feng-Ling Liao, from Wuzhou
Center for Disease Prevention and Control in China; Jin-Lan Xie from the
Wuzhou Worker's Hospital in China; Enrico Pira from the University of Turin
in Italy; and Zheng. The research has focused on China because that country
is a major manganese ore producer and provides one-third of the world's
supply of steel alloys. The paper includes data from research involving a
female Chinese mineworker who suffered debilitating symptoms, including lack
of coordination, trouble walking and writing, and a masklike appearance
caused by tense facial muscles. The woman's symptoms nearly disappeared after
treatment with PAS in 1987, and she remained free of symptoms when
re-examined during a follow-up study in 2004. The researchers suggest several
possible mechanisms that enable the drug to reverse symptoms of the illness.
One is that the drug may contain "chelating arms" that grab manganese.
"However, we are not just looking at this drug as a chelating compound, but
also as an anti-inflammatory, like aspirin," Zheng said. "Historically, we
have believed that neurodegeneration is permanent and cannot be reversed, but
PAS appears to shed light on a reversal mechanism. "It may possibly repair
neurons. If this is true, this would be a major finding, but further research
will be needed to study this possibility. We think the bigger picture is that
the drug might also be used as a treatment for Parkinson's disease, but much
more work is needed to confirm this theory."

----------------------------------------------------------------------
To sign-off Parkinsn send a message to: mailto:[log in to unmask]
In the body of the message put: signoff parkinsn